HIGHLIGHTS
SUMMARY
It affects over 70 million people, one-third of which is drugresistant (Löscher et_al, 2020; Fattorusso et_al, 2021). Despite the advances in the field of epilepsy and the recent approval of new antiseizure medications (ASMs), DRE still represents a major problem (Yoo and Panov 2019; Fattorusso et_al, 2021). It seems to show a positive response also in patients affected by some encephalopathic epilepsies (Tulli et_al, 2021; Verrotti et_al, 2021). Several trials have proved its effectiveness in DS and LGS patients (Devinsky et_al, 2017; Lattanzi et_al, 2019; Verrotti and Striano 2021). Cenobamate, a novel . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.